Looking at Chimeric Therapeutics Limited's (ASX:CHM ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational ...

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025SOUTH SAN FRANSCISCO, Calif., ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report report ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

China Universal Asset Management Co. Ltd. bought a new stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor ...

Paul Hopper bought 200.00m shares over the last 12 months at an average price of AU$0.008. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on ...